KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $2.2 billion.

  • Teva Pharmaceutical Industries' Long-Term Deferred Tax rose 2178.99% to $2.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 2178.99%. This contributed to the annual value of $2.2 billion for FY2025, which is 2178.99% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Long-Term Deferred Tax of $2.2 billion as of Q4 2025, which was up 2178.99% from $1.6 billion recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Long-Term Deferred Tax peaked at $2.2 billion during Q4 2025, and registered a low of $596.0 million during Q4 2021.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $1.6 billion (2022), whereas its average is $1.5 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Long-Term Deferred Tax soared by 14855.31% in 2022 and then crashed by 2106.28% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Long-Term Deferred Tax stood at $596.0 million in 2021, then surged by 144.63% to $1.5 billion in 2022, then rose by 24.28% to $1.8 billion in 2023, then fell by 0.72% to $1.8 billion in 2024, then grew by 21.79% to $2.2 billion in 2025.
  • Its Long-Term Deferred Tax was $2.2 billion in Q4 2025, compared to $1.6 billion in Q3 2025 and $1.8 billion in Q2 2025.